Skip to main content

Table 3 Selected comorbidities during the 5 years prior to ATTRv amyloidosis diagnosis

From: The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

 

Newly diagnosed ATTRv amyloidosis patients

N = 141

Matched controlsa

N = 423

P value

Newly diagnosed ATTRv amyloidosis patients

N = 141

Matched controlsa

N = 423

P value

Newly diagnosed ATTRv amyloidosis patients

N = 141

Matched controlsa

N = 423

P value

Newly diagnosed ATTRv amyloidosis patients

N = 141

Matched controlsa

N = 423

P value

 

Ocular, and severe organ dysfunction or failure

 

Glaucoma

Vitreous opacity

Renal failure

Organ transplant

N (%)

21 (14.9)

53 (12.5)

0.471

12 (8.5)

18 (4.3)

0.051

28 (19.9)

24 (5.7)

< 0.001

4 (2.8)

0 (0.0)

< 0.001

First evidence occurred, n (%)

  

0.285

  

0.208

  

< 0.001

  

0.007

 No evidence

120 (85.1)

370 (87.5)

 

129 (91.5)

405 (95.7)

 

113 (80.1)

399 (94.3)

 

137 (97.2)

423 (100.0)

 

 Pre Y1

1 (0.7)

0 (0)

 

2 (1.4)

3 (0.7)

 

13 (9.2)

4 (0.9)

 

2 (1.4)

0 (0)

 

 Pre Y2

1 (0.7)

1 (0.2)

 

2 (1.4)

4 (0.9)

 

6 (4.3)

6 (1.4)

 

1 (0.7)

0 (0)

 

 Pre Y3

3 (2.1)

9 (2.1)

 

4 (2.8)

2 (0.5)

 

2 (1.4)

3 (0.7)

 

0 (0)

0 (0)

 

 Pre Y4

1 (0.7)

10 (2.4)

 

2 (1.4)

3 (0.7)

 

2 (1.4)

3 (0.7)

 

1 (0.7)

0 (0)

 

 Pre Y5

15 (10.6)

33 (7.8)

 

2 (1.4)

6 (1.4)

 

5 (3.5)

8 (1.9)

 

0 (0)

0 (0)

 
 

Gastrointestinal

   
 

Diarrhea

Constipation

Nausea/vomiting

Weight loss

N (%)

25 (17.7)

47 (11.1)

0.041

35 (24.8)

49 (11.6)

< 0.001

38 (27.0)

55 (13.0)

< 0.001

19 (13.5)

30 (7.1)

0.020

First evidence occurred, n (%)

  

0.352

  

0.005

  

< 0.001

  

0.003

 No evidence

116 (82.3)

376 (88.9)

 

106 (75.2)

374 (88.4)

 

103 (73.0)

368 (87.0)

 

122 (86.5)

393 (92.9)

 

 Pre Y1

5 (3.5)

8 (1.9)

 

11 (7.8)

11 (2.6)

 

6 (4.3)

5 (1.2)

 

10 (7.1)

5 (1.2)

 

 Pre Y2

4 (2.8)

11 (2.6)

 

9 (6.4)

14 (3.3)

 

4 (2.8)

15 (3.5)

 

0 (0)

7 (1.7)

 

 Pre Y3

6 (4.3)

11 (2.6)

 

5 (3.5)

5 (1.2)

 

8 (5.7)

17 (4.0)

 

3 (2.1)

6 (1.4)

 

 Pre Y4

5 (3.5)

6 (1.4)

 

5 (3.5)

11 (2.6)

 

9 (6.4)

8 (1.9)

 

2 (1.4)

6 (1.4)

 

 Pre Y5

5 (3.5)

11 (2.6)

 

5 (3.5)

8 (1.9)

 

11 (7.8)

10 (2.4)

 

4 (2.8)

6 (1.4)

 
 

Musculoskeletal and cardiovascular

   
 

Spinal stenosis

Carpal tunnel

Congestive heart failure

Hypotension

N (%)

23 (16.3)

43 (10.2)

0.049

13 (9.2)

28 (6.6)

0.030

33 (23.4)

25 (5.9)

< 0.001

26 (18.4)

26 (6.1)

< 0.001

First evidence occurred, n (%)

  

0.012

  

0.104

  

< 0.001

  

< 0.001

 No evidence

118 (83.7)

380 (89.8)

 

128 (90.8)

395 (93.4)

 

108 (76.6)

398 (94.1)

 

115 (81.6)

397 (93.9)

 

 Pre Y1

3 (2.1)

16 (3.8)

 

4 (2.8)

4 (0.9)

 

11 (7.8)

6 (1.4)

 

11 (7.8)

6 (1.4)

 

 Pre Y2

5 (3.5)

6 (1.4)

 

2 (1.4)

6 (1.4)

 

6 (4.3)

3 (0.7)

 

5 (3.5)

6 (1.4)

 

 Pre Y3

3 (2.1)

6 (1.4)

 

3 (2.1)

2 (0.5)

 

7 (5.0)

3 (0.7)

 

3 (2.1)

5 (1.2)

 

 Pre Y4

2 (1.4)

8 (1.9)

 

4 (2.8)

8 (1.9)

 

6 (4.3)

4 (0.9)

 

2 (1.4)

4 (0.9)

 

 Pre Y5

10 (7.1)

7 (1.7)

 

0 (0)

8 (1.9)

 

3 (2.1)

9 (2.1)

 

5 (3.5)

5 (1.2)

 
 

Cardiovascular (continued)

   
 

Dyspnea

Ventricular hypertrophy

Hypertrophic cardiomyopathy

Restrictive cardiomyopathy

N (%)

70 (49.6)

109 (25.8)

< 0.001

28 (19.9)

24 (5.7)

< 0.001

8 (5.7)

2 (0.5)

< 0.001

11 (7.8)

8 (1.9)

< 0.001

First evidence occurred, n (%)

  

< 0.001

  

< 0.001

  

0.003

  

< 0.001

 No evidence

71 (50.4)

314 (74.2)

 

113 (80.1)

399 (94.3)

 

133 (94.3)

421 (99.5)

 

130 (92.2)

415 (98.1)

 

 Pre Y1

9 (6.4)

15 (3.5)

 

8 (5.7)

6 (1.4)

 

3 (2.1)

1 (0.2)

 

1 (0.7)

0 (0)

 

 Pre Y2

12 (8.5)

15 (3.5)

 

6 (4.3)

6 (1.4)

 

2 (1.4)

0 (0)

 

4 (2.8)

0 (0)

 

 Pre Y3

9 (6.4)

21 (5.0)

 

5 (3.5)

6 (1.4)

 

1 (0.7)

1 (0.2)

 

1 (0.7)

2 (0.5)

 

 Pre Y4

15 (10.6)

16 (3.8)

 

4 (2.8)

1 (0.2)

 

1 (0.7)

0 (0)

 

3 (2.1)

0 (0)

 

 Pre Y5

25 (17.7)

42 (9.9)

 

5 (3.5)

5 (1.2)

 

1 (0.7)

0 (0)

 

2 (1.4)

6 (1.4)

 
 

Nervous system and metabolic

  
 

Neuropathy

Incontinence

Diabetes

N (%)

37 (26.2)

25 (5.9)

< 0.001

20 (14.2)

23 (5.4)

< 0.001

56 (39.7)

107 (25.3)

0.001

First evidence occurred, n (%)

  

< 0.001

  

0.005

  

0.022

 No evidence

104 (73.8)

398 (94.1)

 

121 (85.8)

400 (94.6)

 

85 (60.3)

316 (74.7)

 

 Pre Y1

17 (12.1)

7 (1.7)

 

2 (1.4)

2 (0.5)

 

4 (2.8)

8 (1.9)

 

 Pre Y2

7 (5.0)

4 (0.9)

 

1 (0.7)

4 (0.9)

 

6 (4.3)

12 (2.8)

 

 Pre Y3

6 (4.3)

4 (0.9)

 

5 (3.5)

2 (0.5)

 

4 (2.8)

3 (0.7)

 

 Pre Y4

1 (0.7)

3 (0.7)

 

6 (4.3)

7 (1.7)

 

10 (7.1)

16 (3.8)

 

 Pre Y5

6 (4.3)

7 (1.7)

 

6 (4.3)

8 (1.9)

 

32 (22.7)

68 (16.1)

 
  1. ATTRv hereditary transthyretin
  2. aMatched with age, gender, and region